Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy;
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …

Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many
cancers, including∼ 12% of acute myeloid leukemia (AML). In preclinical models these …

Alterations to genes involved in cellular metabolism and epigenetic regulation are
implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate …

Abstract Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism,
epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the …

Abstract Isocitrate dehydrogenase (IDH) 1 and 2 mutations result in overproduction of D-2-
hydroxyglutarate (2-HG) and impaired cellular differentiation. Ivosidenib, a targeted mutant …

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert
isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including …

DNA methylation has pivotal regulatory roles in mammalian development, retrotransposon
silencing, genomic imprinting, X-chromosome inactivation, and cancer. Cancer cells display …

The most frequently mutated metabolic genes in human cancer are those encoding the
enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2; these mutations have so far been …